Table 2.
Baseline characteristics in the CRPC cohort according to results of whole genome arrays
| LPD1 (n=14) | Non-LPD1 (n=44) | p value | |
|---|---|---|---|
| Performance status | |||
| ECOG 0 | 4 (28.6%) | 13 (29.5%) | 0.944 |
| ECOG 1 | 10 (71.4%) | 31 (70.5%) | .. |
| Age, years | |||
| Median (range) | 67.3 (46.0–79.8) | 68.6 (53.1–83.1) | 0.501 |
| Gleason score | |||
| Score ≤7 | 5 (38.5%) | 14 (36.8%) | 0.917 |
| Score >7 | 8 (61.5%) | 24 (63.2%) | .. |
| Unknown | 1 | 6 | .. |
| PSA, ng/mL | |||
| Median (range) | 373 (20–3683) | 85 (1–3609) | 0.002 |
| PSADT, months | |||
| Median (range) | 2.3 (0.8–14.4) | 2.9 (0.5–16.0) | 0.148 |
| Albumin, g/L | |||
| Median (range) | 3.2 (2.7–4.1) | 3.7 (2.9–4.5) | 0.002 |
| Alkaline phosphatase, IU/L | |||
| Median (range) | 519 (75–2684) | 88 (46–2166) | <0.0001 |
| Lactate dehydrogenase value over UNL | |||
| Median (range) | 1.2 (0.8–3.9) | 0.9 (0.7–34) | 0.031 |
| CTCs per 7.5 mL | |||
| Median (range) | 133 (0–643) | 4 (0–168) | 0.033 |
| Treatments | |||
| LHRHa | 14 (100%) | 44 (100%) | 1.000 |
| Antiandrogens | 14 (100%) | 30 (100%) | 1.000 |
| Steroids | 4 (28.6%) | 14 (31.8%) | 0.818 |
| Docetaxel | 6 (42.9%) | 10 (22.7%) | 0.177 |
| Number of systemic treatment lines | |||
| Median (range) | 3 (1–8) | 2 (1–7) | 0.076 |
Six patients with CRPC were not classified by LPD analyses. ECOG=Eastern Cooperative Oncology Group. PSA=prostate-specific antigen. PSADT=PSA doubling time. UNL=upper normal limit. CTC=circulating tumour cell. LHRHa=luteinising hormone releasing hormone analogue.